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Abstract Systemic lupus erythematosus (SLE) is con-
sidered an autoimmune disease with multiorgan involve-
ment. Many advances have been made during the last
decade regarding inflammatory pathways, genetic and
epigenetic alterations, adaptive and innate immune system
mechanisms specifically involved in SLE pathogenesis.
Apoptosis has been proposed as an important player in SLE
pathogenesis more than a decade ago. However, only
recently new key apoptotic pathways have been investi-
gated and the link between apoptotic debris containing
autoantigens, innate immunity and ongoing inflammation
has been further elucidated. Better understanding of cel-
lular mechanisms and involved cytokines contributed to the
development of new biological drugs specifically addressed
for SLE therapy.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by protean clinical manifestations,
multiorgan involvement and unpredictable course [1].
SLE incidence has been estimated ranging 1–10 cases
per 100,000 persons for year and the prevalence has been
reported to range between 20 and 150 cases every 100,000
persons. Genetic and environmental factors play a key role
probably explaining not only different geographical prev-
alence, but also disease severity and course in different
patients. Overall the incidence of SLE is higher in African
American, Hispanic and Asian individuals than Cauca-
sians. SLE usually affects women during their reproductive
years with a 9:1 female to male ratio [2–5].
SLE has classically been considered an autoimmune
disease with a predominant adaptive immune system
component, since T cells and recently B cells have been
considered the most important pathogenetic player [6].
More recently, many studies also focused on innate
immune system, and in particular on dendritic cells and
phagocytes, since their ability to interact with autoantigens
during the early inflammatory phase. These cells are indeed
responsible for antigen processing, presentation and sec-
ondarily for activation of the adaptive immune system
[7, 8].
SLE genetical consideration
It has been shown that monozygotic twins display a higher
rate of concordance, when compared to dizygotic ones (34
vs 3 %), regarding the risk of developing SLE. Several
genes seem to increase SLE susceptibility. However,
genetic mutations that cause the disease in a Mendelian
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fashion account only for a small percentage of SLE cases.
For the majority of patients, a combination of genes,
instead of a single gene, predisposes to the disease, in
particular when interaction with environmental factors
occurs [9].
For example some class major histocompatibility com-
plex antigens, in particular from class II genes (HLA-DR,
DQ and DP), have classically been associated with SLE
susceptibility [10]. Homozygous C1q deficiency and genetic
mutations determining low levels of C2 and C4 are associ-
ated with an increased risk of developing SLE, probably
since low complement activity contributes to defective
clearance of the apoptotic material and consequently deter-
mines accumulation of potential autoantigens [11]. Recently
low levels of mannose-binding lectin (MBL), a C1q-related
protein with a crucial role in opsonizing mannose-rich
microorganisms and activating complement classical path-
way, have also been described in SLE patients [12].
Peripheral blood mononuclear cells isolated from SLE
patients, particularly when the disease is characterized by
severe renal involvement, usually display high IFN-I
activity detected using a microarray IFN-genetic signature
technique [13, 14]. These patients present indeed an
overexpression of the interferon regulatory factor 5, a
transcription factor of plasmocytoid dendritic cells (pDCs)
[15]. The recent observation that an increased genetic IFN-
a activity has been also described as an heritable risk factor
for lupus, confirms the importance of IFN-I system for SLE
pathogenesis [16].
DNA methylation and histone modification are key
mechanisms of human epigenetic control on gene expres-
sion. SLE patients with active lupus were found to have a
reduced capacity of DNA methylation of several genes,
leading to an overexpression of inflammatory proteins such
as CD11a, CD70, CD40L. Perforin overexpression, due to
gene hypomethylation, is responsible of abnormal CD4? T
lymphocytes killing activity [17, 18]. Some drugs such as
hydralazine or procainamide, well known for being asso-
ciated to drug-induced lupus, could also determine DNA
hypomethylation. Furthermore, in SLE patients, DNA hy-
pomethylation increases apoptotic rate on peripheral blood
mononuclear cells [19].
MicroRNAs (MiRNAs), non-coding molecules that
regulate the expression of target genes in a post-tran-
scriptional manner, could control both DNA methylation
and histone modifications. Abnormal patterns of MiRNAs
have also been demonstrated in SLE patients [20, 21].
The role of hormonal and environmental factors
Many theories have been postulated in the past to explain
why SLE has a so strong female predominance [22, 23]. A
key role has been attributed to estrogens’ signal through the
receptor a. Previous studies have reported that females
with SLE present increased level of estrogens and reduced
level of androgens, probably due to increased aromatase
activity, an enzyme that converts androgens into estrogens
[24, 25]. Very interestingly, the first effective mouse model
of renal lupus was described in New Zealand black 9
white female (NZB/WF) mice. Although there have been
subsequent descriptions of lupus in male murine strains,
NZB/WF mice model brought the very first scientific evi-
dence for a role of sex hormones in SLE immune responses
[26, 27].
The increased risk of SLE flare during pregnancy may
be related to the higher amount of sex hormones even if
circulating estrogens’ levels are not considered good pre-
dictors of disease flares. In vitro studies demonstrated an
increased production of inflammatory cytokines, especially
IFN-a, from dendritic cells (DCs) exposed to estrogens
[28]. An increased cytokine production has also been
revealed in T and B lymphocytes exposed to estrogens,
probably due to NF-kB activity modulation. By contrast,
progesterone could block Toll-like receptor (TLR)-7,
inducing a reduction of inflammatory cytokines [29].
During puerperium, the clinical course of several autoim-
mune diseases can classically get worse. This is probably
due to increased levels of circulating prolactin, a hormone
well known for its stimulatory effects on the immune
system especially on B cells [30].
The role of infections has been also regarded for a long
time as an important trigger for both SLE induction during
early phases and later for exacerbations during disease
course. Complement deficiencies, MBL pathway alteration,
FCcRs polymorphism have been already described as
susceptibility genes, implicating that abnormalities in
defense mechanisms may ultimately predispose individuals
to SLE [31, 32].
Cross-reactivity between self and non-self microbial
epitopes seems to be a pivotal mechanism in breaking the
immune tolerance. Such molecular mimicry has been for
example described between EBV nuclear antigen-1 and
self-antigens. Chronic active EBV infection could promote
the continuous production of IFN-I and up-regulate TLR
expression from innate immunity cells [33, 34]. Further-
more, as discussed above, bacterial and viral hypomethy-
lated DNA are very efficient in activating the innate
immune system through TLR system.
Ultraviolet (UV) light induces apoptosis in keratinocytes
and causes translocation of autoantigens from cellular
compartment to membranal surface on apoptotic blebs.
UVB exposition seems to specifically promote plasmocy-
toid DC recruitment into cutaneous lesions of SLE patients.
pDC can subsequently present apoptosis-associated auto-
antigens to lymphocytes and induce specific adaptive
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humoral and cellular responses. Increased levels of IFN-a
have indeed been demonstrated in skin specimens from
SLE patients. Moreover, UV light increases the production
of other inflammatory cytokines, such as IL-1, IL-6 and
TNF-a by keratinocytes and lymphocytes. UV light,
apoptotic mechanisms and IFN-a production by pDCs play
a crucial role in SLE pathogenesis, in accordance with the
well-known described phenomena of cutaneous and not
rarely systemic flare after sunlight exposure for SLE
patients [35, 36].
Several drugs, such as procainamide, hydralazine and
quinidine have been described as trigger factors for SLE. In
the majority of cases, however, drug-induced autoimmu-
nity consists only of circulating autoantibodies without the
development of overt SLE symptoms. Indeed, true drug-
induced lupus usually manifests with skin, joint inflam-
mation or constitutional symptoms (such as fever and
asthenia); however, kidney, heart or brain are very rarely
involved. As previously stated, reduction in DNA meth-
ylation activity can explain for some cases the pathogenesis
of drug-induced SLE that usually resolves completely after
drug discontinuation [37].
Apoptosis
Apoptosis is a programmed cell death (PCD), that can be
triggered by different internal, such as DNA mutation, or
external, such as infections and UV exposure, trigger fac-
tors. Apoptosis is a fine regulated process, which requires
energy with ATP consumption, sequential activation of
intracellular enzymes with protease activity (caspases),
digestion of chromatin and DNA by DNase enzyme, and
finally cytoskeleton modification with formation of mi-
croparticles from the membrane. However, unlike necrosis,
the integrity of cellular membrane during apoptosis is
preserved and the intracellular content is not released into
the extracellular compartment. Anyways, a prompt clear-
ance of apoptotic cells is needed under normal circum-
stances from phagocytes and macrophages, which
recognize, adhere, engulf and ultimately digest apoptotic
debris. Probably the phosphatidylserine exposed early on
the external membrane during apoptosis phases plays a
major role for phagocytic recognition; however, the precise
involved receptors are not yet completely understood and
identified. Notably, the interaction between macrophages
and apoptotic cells determines a tolerogenic immunologi-
cal response, characterized by release into the microenvi-
ronment of TGF-beta and IL-10, which ultimately prevents
the beginning of inflammation [38, 39].
During apoptosis, cells undergo profound modification
such as nuclear fragmentation, cytoskeleton rearrangement
and membrane blebbing. As a consequence, apoptosis-
modified or cryptic autoantigens, which are normally not
exposed to the immune system, are transitory expressed
on apoptotic cell membranes or apoptotic debris, such as
microparticles, generating during the process of cell death.
A normal and effective function of phagocytic cells is
physiologically fundamental for maintaining a rapid and
complete clearance of apoptotic cells, which would
otherwise evolve into secondary necrosis. This last cir-
cumstance would determine the release of ‘‘danger sig-
nals’’ molecules, normally enclosed inside the cytoplasm,
into the extracellular environment, and would begin an
inflammatory response characterized by cytokine release
and production of autoantibodies [40, 41]. For example,
high mobility group box protein 1 (HMGB1), produced
during cell activation and during apoptosis in attempt to
stabilize the nucleosome structure, shows strong proin-
flammatory activity when released into extracellular
compartment. HMGB1 has indeed been identified as
‘‘alarmin’’ able to amplify inflammation and enhance
immune responses by interacting with the receptor for
Advanced Glycation End Products (RAGE) and TLRs 2,4
and 9 [42, 43].
As a consequence of defective apoptosis clearance in
human SLE, patients present circulating self-DNA or self-
RNA complex that becomes antigenic targets for both
humoral and cell-mediated autoimmune responses.
In a murine model of SLE, an increased apoptosis rate
usually results in lupus-like features. On the other hand,
such an increase has not been shown in human SLE that
has been predominantly associated with a reduction of
apoptotic bodies’ clearance from phagocytic/macrophage
system. In both cases, the final result is always an increased
apoptotic burden that determines the recognition of apop-
totic-derived autoantigens and hyperactivation of innate
and adaptive immune system cells.
Dendritic cells and innate immunity activation
DCs can recognize damage-associated molecular pattern,
as not only microbial but also as endogenous ligands, via
pathogen recognition receptors and, particularly, through
TLRs. TLRs are a family of transmembrane proteins,
expressed by not only innate and adaptive immune system
cells, but also by some epithelial cells, which recognize
various pathogen molecular patterns from bacteria, viruses,
fungi or protozoan parasites [44]. TLRs are located both on
the surface and in the cytosol of different cells; anyways,
these receptors are particularly expressed in antigen-pre-
senting cells. For SLE pathogenesis, nucleic acid-sensing
TLRs (TLR3, TLR7, TLR8 and TLR9) are of particular
interest since they recognize and bind DNA- or RNA-
containing antigens. In particular, TLR7 recognizes single-
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stranded RNA, while TLR9 is considered very efficient in
binding unmethylated CpG DNA. The strategic intracel-
lular location of these two TLRs minimizes accidental
exposure to self-nucleic material, since their activation is
under normal circumstance triggered by nuclear material
from viral or microbiological origin. The inflammatory
cascade from TLRs is particularly effective when the
nucleic acid material is delivered in the form of immuno-
complex, since a second signal from Fcc receptors is
usually needed to amplify the immunological response.
Both TLR7 and TLR9 stimulate the production of type I
interferon through key adaptor molecules such as MyD88,
a critical protein in IFN alfa production. During SLE
pathogenesis, the activation of intracellular TLRs is not
driven by microbiological nuclear material, since the
inflammatory response is maintained by material of apop-
totic origin [45, 46]. Actually in SLE predisposed subjects,
endogenous TLRs ligands, such as DNA- or RNA-con-
taining particles generated from apoptosis, can activate the
innate immune system. An increased level of circulating
DNA, RNA and nuclear proteins has been shown in blood
from SLE patients [47].
The most significant amount of evidence in the context
of SLE involves the above-mentioned endosomal receptors
TLR7 and TLR9. For example, an increased expression of
TLR9 in B cells and monocytes has been described in
active SLE patients [48]. Moreover, in this context, envi-
ronmental factors, such as viral infections, could also
contribute to disease flares determining a further activation
of TLRs and IFN-I systems.
Under normal circumstances, immature DCs present
self-antigens without costimulatory signals, inducing a
tolerogenic effect on autoreactive lymphocytes. However,
under certain proinflammatory conditions, which are able
to induce DC maturation, self-antigens are presented to T
lymphocytes in the presence of costimulatory signals,
promoting an autoimmune response [49, 50]. While mye-
loid DCs (mDCs) are able to recognize, phagocyte and
present uncomplexed apoptotic material, pDCs usually
recognize immune complex (IC) containing apoptotic
material and are very efficient in producing large amounts
of IFN-a. Although any cell can virtually produce type I
IFN, pDCs are undoubtedly considered the major produc-
ers of this family of cytokines, which comprises 13 dif-
ferent IFN-a isoforms as well as IFN-b, IFN-e, IFN-j, and
IFN-x. Many different ICs can activate pDCs, but as dis-
cussed above RNA-containing ICs seems to be the best
IFN-a inducing stimulus, owing to the simultaneous
binding of Fcc and intracytosolic TLRs. Type I IFN family
presents many immunological functions, such as promotion
of B cells’ differentiation, immunoglobulin class switch,
production of autoantibodies and increase of activated B
and T cells survival.
In healthy individuals, IFN-I released from pDCs is
usually triggered by viral infection, but under such cir-
cumstance IFN-I production is only temporary, strictly
regulated and limited in time with resolution of the viral
infection. This is not the case of SLE, since IFN release
under such condition is independent from the infectious
stimulus and driven mainly by nuclear debris recognized as
autoantigens. Direct estimate of circulating IFN level is
usually very complicated and not completely reliable;
however, recent studies have shown a good correlation
between expression of IFN-inducible genes in peripheral
blood mononuclear cells, using a microarray device, and
SLE activity [51]. Such a hyperactivation of IFN-genes,
more commonly known as ‘‘interferon signature’’, in SLE
patients has not only been demonstrated on the circulating
mononuclear cells, but also locally on the glomerular,
synovial and cutaneous tissues, suggesting a key pathoge-
netic role of IFN type I family in such disease [52].
Interestingly, interferon pathway has been shown to induce
and drive SLE inflammation in several, but not in all,
murine experimental models, suggesting different SLE
pathogenetic subsets [53–56]. Nevertheless, lupus-like
syndrome is a very well-known complication of recombi-
nant IFN-a therapy administered for chronic hepatitis or
cancer treatment [57, 58].
Although neutrophils have long been considered to be
associated with lupus, their potential role in disease path-
ogenesis has only been recently more deeply investigated
[59]. Neutrophils, the most abundant leukocyte in humans,
are typically recruited to sites of infection during the early
phases of inflammatory responses and are considered the
primary cellular defense against bacterial and fungal
infections. They are able to kill pathogens using phago-
cytosis, producing reactive oxygen species or releasing
preformed cytotoxic molecules from cytoplasmatic gran-
ules into the extracellular compartment. Very recently,
another killing mechanism has been discovered, during
which neutrophil extracellular traps (NETs), meshworks
structures consisting of chromatin and peptides with anti-
microbial activity, are released from dying cells [60]. This
specific form of neutrophils PCD has been so-called
‘‘NETosis’’ and has been involved in autoimmune diseases
pathogenesis [61].
Neutrophil-derived structures, containing a significant
amount of DNA and ribonucleoproteins, are potentially
able to stimulate pDC to produce interferon alfa, princi-
pally through interaction with TLR9 [62]. In about one-
third of SLE patients, an abnormal NET accumulation has
recently been demonstrated, due to low DNase (deoxyri-
bonuclease) I activity, the main enzyme responsible of
NET clearance in humans, in these ‘‘non degraders’’
patients. This is particularly important since the non-
degrader phenotype carries a more than 70 % risk of lupus
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nephritis compared to just 25 % of normal degrader SLE
patients [63].
Further studies will be required for a better compre-
hension of IFN-I and DC role in SLE pathogenesis but, to
date, they seem to play a key role at the interface between
innate and adaptive immunity, as reported in Fig. 1.
Adaptive immunity
Under physiological conditions, T cells undergo activation
only when mature DCs present self-antigen in MHC-
restricted conditions. In SLE patients, T cells hyperactivity
has been described, since the engagement of T cell receptor
(TCR) with MHC, in conjunction with costimulatory sig-
nals, leads to a vigorous intracytoplasmic calcium flux and
produce an aberrant downstream cellular activation. CD3f
chain is a crucial component of the TCR complex, playing
an important role in determining the intracellular signal
transduction pathway [64, 65].
CD4? T helper cells are classically distinct in Th1 and
Th2, according to cytokine production and to their func-
tions (allergic reaction for Th2, defense against infection
for Th1). IL-12 stimulates the differentiation of naı¨ve
CD4? T cells into Th1 cells, which in turn produce IFN-c.
On the other hand, IL-4, IL-5 and IL-13, cytokines mainly
produced by Th2 lymphocytes, are involved in many
functions of T and B cells including proliferation, activa-
tion and isotype switching.
Th17 cells, involved in pathogenesis of several auto-
immune diseases such as rheumatoid arthritis or inflam-
matory bowel diseases, are a subset of T helper
lymphocytes producing the cytokines of IL-17 family.
Recently, a crucial role has also been demonstrated for
Th17 lymphocytes in SLE [66, 67]. Th17 cells indeed have
been found in glomerular tissue from patient with active
lupus nephritis. Increased levels of IL-6 and IL-21, both
influencing Th-17 differentiation and response, have also
been demonstrated in SLE [68, 69]. Recently, Savino et al.
have shown, both in mice and humans, a possible role of
the SHC adapter family member, Rai. Indeed Rai(-/-)
mice develop a lupus-like phenotype with a spontaneous
activation of self-reactive lymphocytes; moreover, it has
been demonstrated that Rai(-/-) mice present Th1 and
Th17 cell infiltrates in the kidneys, suggesting that Rai
knockout mice (-/-) is more susceptible to lupus
nephritis. Finally, T cells derived from SLE patients
demonstrated a defect in Rai expression, suggesting a
possible role of this adapter protein as an immunomodu-
lator/immunosoppressor in SLE pathogenesis [70].
Several studies focused on regulatory T cells (Treg) as
potential players of the break down of immune tolerance,
since both quantitative and qualitative abnormalities of
peripheral regulatory T lymphocytes (CD4? CD25? high)
were demonstrated in SLE patients [71, 72]. The deficiency
of regulatory activity in SLE can be explained partially
both by decreased production of IL-2, the main cytokine
driving development and survival of T reg, and by the
IFN-α
Lymph
B
Lymph T
CD4+
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apoptotic bodies
Role of innate immunity in SLE
Endothelial cells
Fig. 1 Both myeloid DCs
(mDCs) and plasmocytoid DCs
(pDCs) produce IFN-a in
response to self-nucleic acids
antigens and self-nucleic acids
in the form of immune
complexes, respectively. IFN-a
presents many immunological
functions, including promotion
of B cells differentiation,
immunoglobulin switch,
autoantibodies’ production and
increased survival of activated
B and T lymphocytes. IFN-a
also activates mDCs and
contribute to direct endothelial
cell damage and promotes
accelerated atherosclerosis
(mDC myeloid dendritic cells,
pDC plasmacytoid dendritic
cells, Lymph B B lymphocytes,
CTL cytotoxic T lymphocytes,
IFN interferon
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contemporary increased levels of IL-6, a circulating factor
profoundly influencing the differentiation of Th17, whose
functions usually counteract T reg functions [73–75].
Further studies, however, are needed to better understand
the role of Treg in SLE pathogenesis [76, 77].
B lymphocytes are new player of adaptive immunity in
SLE pathogenesis. They were classically considered fun-
damental for the production of a broad array of autoanti-
bodies against soluble and cellular component, such as
nuclear antigens, typical of SLE patients. Moreover, B
lymphocytes present efficiently autoantigens and activate T
cells, so their action is not only limited to production of
antibodies [78, 79]. Similar to T cells, hyperactivation has
recently also been described for B lymphocytes, since
increased phosphorylation of several signaling molecules
and abnormal calcium flux have been reported in B cells
from SLE patients [80, 81].
B lymphocyte can be classified into at least two lin-
eages: B1 and B2 cells. B1 lymphocytes, which have been
mainly studied in mice, are considered self-renewing and
long-lived cells and are specialized in producing polyre-
active ‘natural’ IgM class antibodies for immediate
defense; they are also thought to clear apoptotic material
and debris, linking innate and adaptive immunity together.
B2 cells are generated in the bone marrow, where autore-
active cells are first removed (central tolerance), and then
undergo further selection in the spleen microenvironment
(peripheral tolerance). After this selection phase, B2 cells
either become mature follicular cells, that migrate
throughout the secondary lymphoid organs waiting for T
cell-dependent activation, or marginal zone (MZ) B2 cells,
which, like B1 cells, are able to respond immediately to
pathogens independently of T cell help.
Although the role of MZ B cells in autoimmunity and in
lupus is still debating, they are probably involved in some
autoimmune diseases, such as autoimmune thrombocyto-
penia, for which splenectomy is beneficial [82–84].
The number of MZB cells has been demonstrated to be
increased in the NZB/WF1 mice model of SLE; moreover,
IFN is a potent driver of their activation and an efficient
enhancer of costimulatory molecules’ expression, making
MZB cells an important player in SLE in particular for
autoantibody production [85, 86]. Finally IgD? CD27?
memory B cells, which include a particular transient dif-
ferentiation stage of memory B cell and circulating MZ B
cells, are fundamental for determining clinical outcome in
RA and SLE after B depletive therapy, since a delayed
repopulation after such a treatment is associated with a
better clinical response [87, 88].
Very recently, a new subset of B lymphocytes has been
described, endowed with immunosuppressive activity and
so referred as regulatory B cells or simply as ‘‘B reg’’. The
main function of regulatory B cells is the production of IL-
10, so that the intracellular staining for this cytokine is
currently the main method for identifying these cells, even
if the recently described B population CD24highCD27??
probably include the large proportion of human Breg [89,
90]. The immunosuppressive properties of IL-10 are well
established in animal models of collagen-induced arthritis
and experimental autoimmune encephalitis; however, the
function of IL-10 in SLE has been very controversial [91,
92]. Recent data seem to indicate a role of IL-10 producing
B reg in SLE too, particularly during active disease to
control the inflammatory response and restore immune
tolerance [93]. Interestingly, after depletion of B cells
using anti-CD20 treatment (Rituximab), the following
repopulation phase is probably constituted mainly of reg-
ulatory B cells and this is particularly true for patients who
achieved a good clinical response. However, further data
are necessary to better clarify the role of Breg cells and IL-
10 in SLE pathogenesis [94, 95].
As previously stated, an elevated level of cytokines that
affect B cell activation and proliferation has been described
in SLE [96]. Increased levels of B lymphocyte stimulator
(BAFF/BLyS) and A proliferation-inducing ligand
(APRIL), promoting autoreactive lymphocytes survival
and autoantibody responses, were also abundantly descri-
bed in human and mice SLE models, indeed both these
factors are target of recently developed drugs for lupus [97,
98]. Interestingly, memory B lymphocytes are independent
from BLyS; survival of mature B cells is promoted both by
BLyS and APRIL; plasma cells survival is essentially
stimulated by BLyS. SLE activity correlates with BLyS
mRNA expression in leukocytes and recently BLyS has
emerged as a new therapeutic target in SLE treatment [99,
100].
Figures 2 and 3 illustrate the complex interplay between
T and B lymphocytes, underlining the role of different
pathogenetic pathways. The deregulation of the adaptive
immunity results in a wide broad of effects. Autoantibody
production, as well known, represents one of the most
important mechanisms contributing to tissue damage.
New therapeutic perspectives: biological agents for SLE
Until recently, few biological agents have been used on a
limited number of SLE patients often with no large con-
trolled-randomized controlled trials supporting efficacy for
such therapies. The lack of new drugs or biological agents,
if compared to other autoimmune disease such as rheu-
matoid arthritis or inflammatory bowel diseases, accounts
for the current broad use of traditional immunosoppressor
drugs, in particular of cyclophosphamide and mycophen-
olate, for severe SLE cases and for the broad number of
drug side effects experienced by SLE patients during their
38 Autoimmun Highlights (2014) 5:33–45
123
lifetime. New data coming from research studies on dif-
ferent inflammatory pathways and cellular interplay
recently produced essential information on new targets for
developing biological drugs in SLE. As summarized in
Fig. 3, the main targets of new SLE therapies are repre-
sented by neutralization of autoreactive B cells, induction
of tolerance, inhibition of costimulatory signals and mod-
ulation of cytokines pathways. Due to the recent light on
SLE pathogenesis, B cells in particular represent a major
therapeutic target of new biological agents. Current and
ongoing therapeutic approaches targeting B cells include
direct depletion of B cells and inhibition of specific B cell-
stimulating cytokines [101, 102].
Rituximab is a chimeric monoclonal antibody (mAb)
against B lymphocytes CD20 antigen, already approved for
lymphoma and rheumatoid arthritis that induces pro-
foundly circulating B cells’ depletion soon after adminis-
tration. Rituximab has been regarded as a promising agent
for active SLE refractory to traditional immunosuppressive
drugs. In murine models, rituximab worked depleting B
cells from the pre-B stage to the mature lymphocyte and
memory B cells. Unlike mice, in humans, rituximab targets
a more narrow spectrum of B lymphocytes, ranging pre-B–
mature B cells. Plasma cells or memory B cells are indeed
not affected by rituximab therapy in humans, since CD20 is
not anymore expressed on membrane surface of these cells.
This also explains why circulating antibodies’ level is
usually preserved during rituximab treatment, unless
repeated cycles of the drug are used [103, 104]. Clinical
experience and several open case series suggested a clinical
improvement and a consistent reduction of SLE activity
disease index (SLEDAI, BILAG) when this biological
agent was used for SLE patients [105]. However, two
double-blind placebo-controlled trials (EXPLORER and
LUNAR) subsequently failed to meet the primary end-
points in systemic and renal SLE, respectively [106, 107].
Despite the normalization of anti-dsDNA and complement
levels in the treated group, clinical outcomes did not differ
significantly between rituximab and placebo group. Further
investigation using different study designs could probably
be useful to clarify the discrepancy between the reported
effectiveness of rituximab for SLE, both in several open
case series and generally in clinical practice, with the
failure to demonstrate any efficacy of the drug in larger
randomized placebo-controlled trials. Important reasons
limiting the potential rituximab benefit in the trials setting
could be represented by the aggressive background
immunosuppressive therapy, the influence of corticoste-
roids used during the study and the too much limited
sample size of enrolled patients. Such considerations
should be kept in mind for further clinical trials with any
investigating agents for SLE [108, 109].
Epratuzumab is a humanized monoclonal antibody
against CD22 antigen, a surface molecule associated to B
cell receptor and endowed with downregulation function. It
also induces reduction of circulating B cells, even if with a
less profound extent comparing to rituximab, since only the
latter is able to induce antibody-dependent cellular
Fig. 2 A As known a
breakdown in the mechanisms
that control the central and/or
peripheral tolerance may lead to
an expansion and differentiation
of autoreactive T cells in turn
able to activate B autoreactive
lymphocytes. B B cells may be
activated classically by T
lymphocytes or alternatively by
direct link between
immunocomplexes containing
self-DNA/RNA and TLRs.
Moreover, BAFF/Blys has
broad potential implications in
SLE pathogenesis, since it
influences peripheral B cell
survival, maturation and
immunoglobulin class switch.
Moreover, BAFF/Blys is
upregulated by IFN-c, IL-10
and CD40 ligand produced
during inflammatory conditions
(TLRs Toll-like receptors, BAFF
B cell activating factor, Blys B
lymphocyte stimulator)
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cytotoxicity on target cells. Unlike rituximab, a slight
reduction of immunoglobulin levels is usually observed
early during treatment. A significant benefit for SLE was
observed during a phase-IIb trial, which employed a new
combined clinical index for evaluating responses. A phase-
III trial on epratuzumab is currently ongoing to confirm
these initial positive results [110].
Belimumab, a fully human IgG1k monoclonal antibody
against BLyS, decreases B cells and level of autoantibod-
ies. BAFF/BLyS pathway plays a key role in the survival
and proliferation of autoreactive B cells [111]. Even if a
phase-II trial was initially not able to reach its primary
endpoints, a post hoc analysis of the data was able to
demonstrate a significant greater response to belimumab in
a subgroup of patients with low complement levels and
anti-DNA positivity [112]. Subsequently, two randomized,
double-blind, placebo-controlled phase-III trials (BLISS-52
and BLISS-76) were performed, using a new index of
clinical response (SLE responder index or SRI). The
BLISS-52 trial, largely conducted in Asia, South America
and Eastern Europe, demonstrated a good response rate at
52 weeks of treatment. SRI rate of responders was 51 %
with 1 mg/kg belimumab dose and 58 % with 10 mg/kg, in
comparison with 44 % in the placebo group [113]. BLISS-
76 trial, which conversely involved US, Western Europe
and Canada, demonstrated a 41 % SRI rate of responders at
1 mg/kg belimumab dose and 43 % at 10 mg/kg, in com-
parison with 34 % in the placebo group [114]. In brief,
Fig. 3 A defective ICs’ clearance due to complement alteration and
increased apoptosis (i.e., UV light induced) lead to the formation of
IC consisting of self-DNA/RNA rich in CpG motifs, hypomethylated,
oxidized. These ICs may bind other molecules such as HMGB1
(released from dead cells) or the antimicrobial peptide LL37-forming
structures capable of inducing pDCs’ activation through different
pathways (i.e., RAGE, FccRIIA and/or TLRs). Of note in SLE
patients, IFN-a activity is increased, since IFN-alfa genetic signature
can be detecting in circulating monocytes using a microarray
technique. (ICs immune complexes, FccRIIA low affinity receptor
for IgG, BCR B cell receptor, HMGB1 high mobility group box 1,
RAGE receptor for advanced glycation end products, LL37 antimi-
crobial peptide or cathelicidin)
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phase-III belimumab trials demonstrated the efficacy of
belimumab in addition to standard therapy compared to
placebo. Belimumab is the only drug currently approved by
the US Food and Drug Administration and recently also by
the European Medicines Agency as the first biologic agent
for SLE patients. Several questions, such as the usefulness
of a long-term treatment and the effectiveness of beli-
mumab in any SLE subset, remain still open. Recent evi-
dences, however, confirmed the safety of belimumab
treatment over 7 years [115].
In addition to belimumab, other agents target the BLyS/
BAFF pathway. Atacicept, a fusion protein between TACI
and the Fc portion of IgG, binds both BLyS and APRIL.
Despite the favorable safety profile demonstrated in pre-
clinical and phase-I studies, a clinical phase-II/III trial in
lupus nephritis was early interrupted because of severe
reduction of B cell number and serum immunoglobulin
levels, which considerably increased severe infections risk.
A new trial, however, is actually ongoing to confirm the
safety and efficacy profile of atacicept [116].
Costimulatory signals, in particular CD40–CD40L
interaction, are crucial for cognate interaction since T cells
are able to stimulate B cells and innate immunity cells
when CD40L (also called CD154) is expressed on their
surface [117, 118]. Despite the effectiveness in a mouse
model, the anti-CD40L monoclonal antibody trials in
humans were early interrupted because of lack of efficacy
compared to placebo and more importantly because of
unexpected elevated incidence of thrombosis in the treated
arm [119, 120]. Despite the negative results, an increasing
amount of data supports the importance of CD40–CD40L
interaction in SLE and prompts the interest in further
exploratory trials with alternative biological agents tar-
geting this pathway [121].
Abatacept, a fusion protein between the extracellular
domain of CTLA-4 and the Fc of IgG1, binds to B7-1 and
B7-2 receptors expressed on antigen-presenting cells such
as B lymphocytes and ‘‘professional’’ APC. A distinguish
feature of CTLA4 is its higher affinity for B7 receptors, if
compared to CD28 expressed on T cells, since its main
function is to downregulate costimulatory signals and limit
immune response. Positive results were initially obtained
from mouse models of SLE and other autoimmune diseases
[122]. For this reasons abatacept was recently evaluated in
SLE with a phase-II randomized, placebo-controlled trial
[123]. Despite a reduction in disease flares, particularly in
patient with articular involvement, no differences were
observed between abatacept and control group regarding
the main endpoints. As mentioned for rituximab, the use of
different response indexes may probably reveal a useful-
ness of abatacept in SLE [124, 125].
TNF-a is a pleiotropic cytokine, produced mainly by
macrophages, and involved in many inflammatory
pathways, with broad stimulatory effects on B and T cells.
TNF-a levels are increased in SLE patients, often in
association with disease activity parameters [126, 127].
Anti-TNF-a agents are the most prescribed biological
drugs used to treat many autoimmune disorders, particu-
larly rheumatoid arthritis, spondyloarthritis and inflamma-
tory bowel diseases. Despite the presumed TNF-a
involvement in SLE pathogenesis, monoclonal antibodies
against TNF-a have not generally used for SLE therapy,
except in limited case series [128, 129]. It is well known
from the literature that TNF blockage can induce autoan-
tibody production and, more rarely, overt drug-induced
lupus-like syndromes, so the use of anti-TNF agents is not
generally accepted or recommended for treating lupus
patients [130, 131].
Tocilizumab, a humanized IgG1 monoclonal antibody
against IL-6 receptor, inhibits the IL-6 pathway that, as
mentioned above, is involved in the development of
inflammation and in B cell activation [132]. The experi-
ence with tocilizumab for SLE is nowadays limited to
sporadic but significant case reports from refractory
patients. Based on the growing evidence suggesting a
pathogenetic role of IL-6, a key cytokine stimulating Th17
differentiation and downregulating T reg cells, the block-
age of IL6 receptor using tocilizumab is considered a very
promising therapeutic option also in SLE, in particular for
patients refractory to conventional therapy [133–135].
Interestingly, a lupus nephritis double-blind phase-II RCT
with sirukumab, an antibody targeting directly IL-6 rather
than IL-6R, is currently on investigation after the drug
showed no toxicity in a previous phase-I study [136].
As described above, IFN-a production is mainly the
result of pDCs’ activation by intracytosolic TLRs binding
with IC containing nuclear material. The subsequent
inflammatory response is therefore responsible of several
steps of SLE pathogenesis, such as T and B lymphocytes’
proliferation. Sifalimumab and rontalizumab, monoclonal
antibodies against IFN-a, are currently evaluated in phase-
II clinical trials [137, 138]. Probably the routine evaluation
of IFN-genes’ overexpression in peripheral monocytes,
using the so-called ‘‘IFN-gene signature’’, will be useful in
the future to identify the subgroup of SLE patients who can
benefit the most from anti-IFN agents. However, it is not
still clear if blocking selectively IFN-alfa will be sufficient
to reverse the inflammatory response and the IFN signa-
ture, considering the many and redundant cytokines
belonging to IFN type I family [139, 140].
Conclusions
Recent advances in our understanding of SLE pathogenesis
have pointed out new targets for treatment but several
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fundamental questions remain unsolved. As for pathogen-
esis, clinical aspects and therapy, SLE remains a very
complex disease, that requires very skilled and highly
trained physicians for a correct clinical evaluation and
diagnosis, for deciding the most suitable therapy in every
single patients and for conducting properly clinical trials.
Indeed different SLE subsets of patients present with dif-
ferent pathogenetic and clinical profiles, requiring diverse
and rather individualized therapeutic approaches, to obtain
the best clinical outcome. Belimumab is the only biological
drug approved for SLE; however, other promising agents
are currently under evaluation with clinical phase-II/III
trials.
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